UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.
UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.
Recruiting · NCT06092047 · Registry updated 2025-05-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies. | CD19-positive Relapsed or Refractory B-cell Malignancies | Recruiting | Early phase 1 | 2025-05-16 | NCT06092047 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Anhui Provincial Hospital | 101 |
| PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 13 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The First Affiliated Hospital of USTC (AnHui Provincial Hospital) | Hefei | China | 1 |